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administration and may consist of a national exam, a state exam, or both. [15:2&3
CRLR 84; 15:1 CRLR 82]
As proposed in December 1994,
BNHA's proposed changes to sections 3116,
3151, 3152, 3160, and 3162, Title 16 of
the CCR, would, among other things, provide that two hours of CE credit shall be
given for attending a public meeting of
BNHA, and eight hours of CE credit will
be given for participating in a Board-sponsored state licensing examination item writing session; BNHA may, in lieu of conducting its own investigation, accept the
findings of the National Association of
Boards of Nursing Home Administrators
regarding CE courses and providers, and
adopt those findings as its own; any licensed NHA may be approved to serve as
a preceptor if the individual, among other
things, has an active NHA license and is
not on probation by the Board; and sixty
hours is the maximum number of hours an
administrator-in-training may work and
train each week. [15:2&3 CRLR 84; 15:1
CRLR 81-82] At its August 17 meeting,
BNHA modified its proposed changes to
section 3116 (regarding applicant qualifications) and deleted all proposed amendments to section 3160 (regarding preceptor qualifications). On August 23, BNHA
released the modified text of section 3116
for an additional 15-day public comment
period; at this writing, the proposed changes
to sections 3116, 3151, 3152, and 3162 are
being reviewed by OAL.
*

LEGISLATION
SB 472 (Petris). Existing law expresses
legislative findings regarding Alzheimer's
disease and states that existing diagnostic
and treatment centers have improved the
quality of care of patients with this disease. Existing law provides that the functions of these centers shall be designed
to serve certain prescribed purposes, including to increase the training of health
care professionals with respect to
Alzheimer's disease. As amended July 19,
this bill amends existing law to provide
that the purpose is to increase the training
of health care professionals with respect
to Huntington's disease also. It authorizes
these centers to develop and approve curricula regarding certain aspects of other
acquired brain impairments. The bill provides that health care facilities, adult day
health care centers, residential care facilities for the elderly, and other providers of
health care or personal care services to
children with disabilities, adults, or older
adults may offer the curricula to employees and it may satisfy up to four hours
annually of any in-service training requirement.

110

Existing law requires the Director of
Mental Health to contract with a nonprofit
agency meeting prescribed criteria to act
as the Statewide Resources Consultant
and prescribes the duties of the consultant
to include, but not be limited to, serving
as an information and technical assistance
clearinghouse for brain-impaired adults,
as defined, and their families, and caregivers, and to develop and conduct related training. This bill specifies that the
duties of the consultant may include reviewing proposed training curricula regarding individuals with brain damage, as
defined, assisting organizations that serve
families with adults with Huntington's disease and Alzheimer's disease in reviewing
data, and forwarding this information to
the appropriate state departments for consideration. This bill was signed by the
Governor on October 4 (Chapter 551, Statutes of 1995).
Future Legislation. At its August 17
and November 30 meetings, BNHA agreed
to pursue several legislative changes. In
addition to a bill increasing the statutory
cap on BNHA licensing fees (see MAJOR
PROJECTS), the Board also intends to
pursue legislation amending Business and
Professions Code section 3905 to clarify
its position regarding the absence of NHAs
for more than thirty consecutive days, the
appointment of acting NHAs, and the deadlines for Board notification; proposed
changes to Business and Professions Code
sections 3924.7 and 3924.8 regarding criminal background checks for applicants and
licensees; and several technical or cleanup changes.

U

RECENT MEETINGS
At BNHA's August meeting, Executive Officer Kim Smith reported that she
and Board member Dr. Orrin Cook are
continuing to meet with various officials
from the Department of Social Services
(DSS) to discuss the future of the residential care facilities for the elderly (RCFE)
administrator certification program; for
many years, BNHA has been considering
assuming RCFE certification responsibilities, which are currently carried out by DSS'
Community Care Licensing Division.
[13:2&3 CRLR 98; 13:1 CRLR 58; 12:4
CRLR 111-12] Smith also noted that the
Community Residential Care Association
of California has already stated its opposition to BNHA's efforts to take over the
certification of RCFE administrators.
Also at BNHA's August meeting, Executive Officer Smith reported that DCA's
Office of Examination Resources had
agreed to conduct an occupational analysis of the NHA profession. Smith expects
that the survey will be completed in Au-

gust 1996; the $10,000 cost for the analysis will be divided between fiscal years
1995-96 and 1996-97.
Also in August, BNHA discussed
staff's proposal to implement Business
and Professions Code section 125.9 by
creating a citation and fine system; such a
system would give staff a means to deal
with minor administrative violations, and
would have the potential to raise additional funding for the Board's operations.
Following discussion, the Board directed
staff to further develop the proposal and
present its findings and recommendations
to the Board. However, at its November
meeting, BNHA tabled the citation and
fine proposal, and directed the Disciplinary Committee to readdress the issue prior
to the Board's next meeting.
At its November 30 meeting, the Board
discussed the upcoming sunset review
process. [14:4 CRLR 20, 87] Executive
Officer Smith urged the Board to immediately begin preparing for the review
process; she requested that the Board appoint a two-member sunset review subcommittee to work with staff in preparing
BNHA's report to the legislature, which is
due in October. Board members Dr. Orrin
Cook and Marilyn Jesswein volunteered
to serve on the subcommittee; Gloria
Johnson will serve as an alternate.

E FUTURE MEETINGS
February 15 in Sacramento.
August 15 in Sacramento.

BOARD OF OPTOMETRY
Executive Officer: Karen Ollinger
(916) 323-8720

p

ursuant to Business and Professions
Code section 3000 et seq., the Board
of Optometry is responsible for licensing
qualified optometrists and disciplining
malfeasant practitioners. The Board establishes and enforces regulations pertaining
to the practice of optometry, which are
codified in Division 15, Title 16 of the
California Code of Regulations (CCR).
The Board's goal is to protect the consumer patient who might be subjected to
injury resulting from unsatisfactory eye
care by inept or untrustworthy practitioners. The Board consists of nine members-six licensed optometrists and three
public members.

U

MAJOR PROJECTS
Board and COA At Stalemate Over
Independent Practice Association
Issue. For over one year, the Board has
been considering two applications for reg-
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istration of optometric corporations; while
the applications specify only one address,
they are apparently intended to be vehicles
for the establishment of "independent
practice associations" (IPAs) whereby optometric services would actually be rendered through numerous optometrists
practicing at different locations. Because
Department of Consumer Affairs (DCA)
legal counsel Robert Miller has interpreted these offices to be "branch offices"
subject to the restrictions and registration
requirement of Business and Professions
Code section 3077, and because both applicants expressly disclaim having any
branch offices, Miller recommended that
the applications be denied. However, the
Board at its December 1994 meeting decided to revisit the section 3077 branch
office restrictions, and scheduled a discussion of this issue for its March meeting.
[15:1 CRLR 83]
At the Board's March 1995 meeting,
Miller reported that he had several conversations with California Optometric Association (COA) legal counsel Mark Andrews regarding this matter. Miller still
contended that by arranging for optometric services to be provided by professional
practitioners, IPAs are effectively practicing optometry at multiple locations in violation of the branch office limitations.
However, Andrews argued that IPAs do
not practice optometry but merely act as
entities which market optometric services,
and thus are not in violation of the branch
office limitations. Miller conceded that
COA's argument may have merit, and informed the Board that there may be alternative interpretations of the law in this
regard. The Board generally agreed that
further research should be conducted to
assist it in determining whether IPAs are
in fact practicing optometry. Accordingly,
the Board unanimously agreed to appoint
a committee, including representatives of
the Board and COA, to study issues concerning IPAs and report its findings and
recommendations to the Board at a future
meeting. [15:2&3 CRLR 85]
Following a further tangle between COA
and Miller at the Board's August meeting,
the Board decided to convene a special
meeting on the IPA issue on September 22.
Miller reiterated his position that the Board
is not authorized to license an IPA as a
professional optometric association as the
IPA inherently violates the branch office
restriction in Business and Professions Code
section 3077. Following extensive discussion, a motion to seek repeal of section 3077
died for lack of a second, leaving the Board
and COA at a stalemate.
At the Board's December meeting,
Miller reported that COA would be seek-

ing an author for legislation which would
exempt IPAs from section 3077's coverage; accordingly, the Board is not expected to take further action on this matter
at this writing.
Rulemaking Update. On May 23, the
Board held a public hearing on the proposed adoption of new sections 1523 and
1524, amendments to sections 1530, 1531,
1532, 1533, 1535, and 1536, and repeal of
section 1526, Title 16 of the CCR, regarding the Board's examination process and
continuing optometric education requirements.
Among other things, these changes
would consolidate the Board's examination and application requirements into one
reference source for licensure candidates;
provide for the approval of the applications for examination for those applicants
who have paid the necessary fees and
whose credentials have been approved by
the Board's Executive Officer; specify
that each applicant for licensure must obtain a passing score of at least 75% in each
of the required examination sections; delete antiquated examination composition
language and clearly delineate each examination section and its composition; clarify that an applicant who has failed to pass
either the Clinical and Demonstration or
Laws and Regulations examination sections after a period of five consecutive
calendar years from the date of the first
examination must retake both examination sections; provide that an inspection
by an examinee of the papers he/she wrote
while taking the Board examination must
be made by that person before the expiration of 90 days after the examination results are mailed; specify that the Board
requires successful completion of the National Board of Examiners in Optometry's
(NBEO) Basic and Clinical Science examination sections as a condition of eligibility to take the Board's Clinical Demonstration and Laws and Regulations examination sections, and delete language authorizing an applicant to otherwise furnish
satisfactory evidence of his/her eligibility
pursuant to the provisions of Chapter 7 of
Division 2 of the Business and Professions
Code; provide that no more than four
hours of continuing education (CE)
coursework shall be in the area of practice
management; provide that CE offerings
approved by the International Association
of Boards of Examiners in Optometry,
known as the Council on Optometric Practitioner Education, are approved as meeting the required standards of the Board;
specify that a licensee is exempt from CE
requirements if he/she was first licensed
by examination within the twelve months
immediately preceding the annual license

renewal date; and provide that, as a condition of license renewal, all licensees are
required to maintain current certification
in cardiopulmonary resuscitation (CPR),
and the training required for the CPR certificate may not be credited toward the
required CE hours. [15:2&3 CRLR 85;
15:1 CRLR 82; 14:4 CRLR 89]
Also on May 23, the Board held a
public hearing on its proposal to amend
section 1560, Title 16 of the CCR, to add
the drug tetracaine hydrochloride, a topical anesthetic with a maximum usage concentration of 0.5%, to the list of topical
pharmaceutical agents which may be used
by Califomia optometrists in their examination of patients. [15:2&3 CRLR 86; 15:1
CRLR 84]
Following the hearing, the Board adopted the changes, which await review and
approval by the Office of Administrative
Law (OAL).
Performance of Ophthalmic Tasks
by Medical Assistants. Over the Board of
Optometry's objections, the Medical
Board's Division of Licensing (DOL)
adopted, at its May 1995 meeting, amendments to section 1366, Title 16 of the
CCR, which defines the technical supportive services which may be performed by
unlicensed medical assistants (MAs). The
amendments would permit MAs to perform ophthalmic testing which does not
require interpretation in order to obtain
test results; delete existing subsection
1366(d) (which prohibits MAs from practicing optometry) as duplicative of existing law; and add a specific reference to
Business and Professions Code section
2069 (which prohibits MAs from administering any local anesthetic agents). [15:2&3
CRLR 65, 86; 15:1 CRLR65-66,83]At this
writing, the rulemaking file on DOL's
amendments is pending review by the DCA
Director, after which it will be submitted
to OAL.

U

LEGISLATION
AB 1107 (Campbell). Under existing
law, the right to sell or furnish prescription
lenses is limited exclusively to licensed
physicians, optometrists, and registered
dispensing opticians. As amended August
28, this bill authorizes, notwithstanding
that limitation, a pharmacist to dispense
replacement contact lenses in accordance
with certain requirements; these requirements are also made applicable to nonresident pharmacists.
Existing law requires nonresident
pharmacies, as defined, to register with the
Board of Pharmacy and to disclose certain
information to that Board and provides for
the denial, revocation, and suspension of
nonresident pharmacy registration for
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failure to comply with certain requirements. This bill adds the requirements for
dispensing replacement contact lenses to
the requirements for which nonresident
pharmacy registration may be denied, revoked, or suspended. The bill requires that
nonresident pharmacies comply with certain requirements, maintain certain records, and disclose certain information to
the Pharmacy Board; adds the requirement that those pharmacies maintain records of all replacement contact lenses
shipped, mailed, or delivered to California
residents; and requires that these records
be available for inspection upon request
by the Pharmacy Board or the Medical
Board's Division of Licensing. This bill
also requires any pharmacy, including
nonresident pharmacies, dispensing replacement contact lenses to comply with
certain laws governing advertising of contact lenses, and to register with DOL at the
time of initial licensure or registration or
upon renewal of the license or registration.
This bill was signed by the Governor on
October 9 (Chapter 719, Statutes of 1995).
SB 640 (Craven), as amended August
29, prohibits, commencing January 1,
1997, any person located outside of California from shipping, mailing, or delivering contact lenses to residents of California unless registered with the Medical
Board's Division of Licensing, and provides that only replacement lenses may be
shipped, mailed, or delivered to a patient.
This bill requires the nonresident contact
lens seller to complete an application, pay
prescribed licensure and renewal fees, and
satisfy various conditions in order to obtain and maintain registration. The bill
provides that contact lenses may be sold
only within one year of the date on the
written prescription, and if the written prescription is unavailable to the seller, it
requires the seller to directly communicate with the prescriber or his/her authorized agent to confirm the prescription. The
bill also sets forth circumstances under
which registration may be denied, suspended, or revoked, and establishes procedures for renewal of registration. It authorizes DOL to adopt regulations necessary to administer these provisions. This
bill was signed by the Governor on October 12 (Chapter 853, Statutes of 1995).
SB 668 (Polanco). Existing law provides that it is unlawful for a person to
engage in the practice of optometry without first obtaining a certificate of registration from the Board. As amended September 14, this bill-which is a reintroduction
of 1993's AB 1894 (Polanco) [14:4 CRLR
89; 13:4 CRLR 781-would authorize ancillary personnel who work under the supervision of an optometrist to assist in the
12

preparation of the patient and the preliminary collection of data. It would prohibit
an optometrist from permitting ancillary
personnel to collect data requiring the exercise of professional judgment or skill of
an optometrist that includes performing
any subjective refraction procedures, contact tonometry, data analysis, or diagnosis,
or prescribing and determining any treatment plan. [S. Conference Committee]
SB 510 (Maddy). Under existing law,
the practice of optometry includes, among
other things, the examination of the human
eye or eyes, or its or their appendages; the
analysis of the human vision system, either subjectively or objectively; and the
use of pharmaceutical agents for the sole
purpose of the examination of the human
eye or eyes for any disease or pathological
condition. Existing law authorizes the Board
of Optometry, with the advice and consent
of the Medical Board of California, to
designate the specific topical pharmaceutical agents to be used for these purposes.
As amended May 2, this bill would state
the intent of the legislature that the scope
of optometric practice be as set forth in
this bill, and that optometrists be prohibited from performing acts outside the scope
of practice as set forth in the bill.
In a modified reintroduction of 1994's
AB 2020 (Isenberg) [14:2&3 CRLR 94],
SB 510 would provide that the practice of
optometry includes, among other things,
the examination of the human eye, or its
appendages, and the analysis and diagnosis of conditions of the human vision system, either subjectively or objectively. The
bill would delete the requirement that the
Board designate the pharmaceutical agents
to be used, and authorize the use of specified diagnostic pharmaceutical agents for
purposes of examining the human eye or
eyes or its or their appendages for any
disease or pathological condition. The bill
would also authorize the use, prescribing,
and dispensing of specified therapeutic
pharmaceutical agents (TPAs) to a patient
by an optometrist for the purposes of treating the human eye or eyes, or its or their
appendages, for any disease or pathological condition by an optometrist who meets
specified requirements. It would exclude
from these TPAs controlled substances specified in state and federal law, and prohibit
the administration by an optometrist of
drugs administered by injection or intravenously. This bill would specify additional practices that are included and excluded from the practice of optometry.
SB 510 would also provide that any
use, prescribing, or dispensing of a pharmaceutical agent to a patient by an optometrist pursuant to these provisions is limited to that which is incidental to the prac-

tice of optometry, and would specify that
dispensing by the optometrist to a patient
be without charge. This bill would make
it a misdemeanor for any person licensed
as an optometrist to refer a patient to a
pharmacy that is owned by that licensee or
in which the licensee has proprietary interest.
Existing law authorizes only a physician, dentist, podiatrist, or veterinarian to
prescribe or write a prescription and to
dispense drugs and devices to patients in
his/her office, under prescribed conditions.
Existing law authorizes the Board to determine educational and examination requirements, with the advice and consent
of MBC, of optometrists to be permitted
to use diagnostic pharmaceutical agents.
SB 510 would instead authorize the Board
to determine educational and examination
requirements, with the advice and consent
of MBC, of optometrists who are issued
an original certificate of registration before January 1, 1996, to be permitted to
use diagnostic pharmaceutical agents. This
bill would establish a seven-member pharmaceutical advisory committee with a prescribed membership to provide advice to
the Board as to the use of diagnostic and
therapeutic agents.
This bill would also authorize the
Board to determine educational and examination requirements, with the advice and
consent of the pharmaceutical advisory
committee established by the bill, for licensure of optometrists who are issued an
original certificate of registration on or
after January 1, 1996, to be permitted to
use diagnostic pharmaceutical agents and
use, dispense, or prescribe TPAs. It would
authorize only optometrists who successfully complete several examination and
training requirements to be permitted to
use, dispense, or prescribe TPAs.
Existing law requires the Board to require, by regulation, that optometrists, as
a condition of licensure renewal, submit
proof of having obtained certain continuing education. This bill would require licensees to complete, at a minimum, 25
hours of continuing education per year,
and would require that one-third of those
hours relate to the diagnosis, treatment,
and management of ocular disease.
This bill would state the intent of the
legislature that to the extent an optometrist's
scope of practice is equivalent to that of a
physician, and optometrist shall be subject
to the same criminal penalties as could be
applied to a physician. [S. B&P]
AB 1969 (Isenberg), as amended April
5, is very similar to SB 510 but would
include within the expanded scope of practice of optometrists the examination of the
adnexa for any disease or pathological
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condition; and would authorize the use,
prescribing, and dispensing of specified
TPAs to a patient by an optometrist for the
purposes of treating the human eye or
eyes, or its or their appendages and adnexa. Also, instead of providing that any
use, prescribing, or dispensing of a pharmaceutical agent to a patient by an optometrist is limited to that which is incidental
to the practice of optometry, AB 1969
would require that such use, prescribing,
or dispensing of a pharmaceutical agent be
limited only to the practice of optometry.
[A. Health]
Future Legislation. At its August 2425 meeting, the Board discussed concerns
about SB 510 (see above), and announced
that it would seek an author for a Boardsponsored scope of practice/TPA bill. On
October 10, however, Senator Polanco
proposed a new COA-sponsored measure-Preprint SB 9-which was apparently drafted without input from the
Board. The measure would create a new
certification program within the Board of
Optometry to certify California optometrists to diagnose and treat certain diseases
and pathological conditions of the eye(s),
impose educational and training requirements on those seeking certification, increase the continuing education requirements and time within which these requirements must be met for license renewal of optometrists certified to treat and
diagnose certain ocular conditions, establish a TPA advisory committee within the
Board, eliminate the advice and consent
authority of DOL concerning the use of
topical pharmaceutical agents, prohibit
optometrists from holding themselves out
to the public as being "specialist(s) in eye
disease," and authorize the Board to impose a new fee relative to the issuing of
TPA certificates. This bill would also
make it unprofessional conduct for an optometrist not to refer a patient to an appropriate physician when response to treatment does not occur within a reasonable
time, and revise the Pharmacy Law in
order to authorize prescriptions by TPAcertified optometrists.
According to the Board, there are several similarities and differences between
SB 510 and Preprint SB 9. For example,
both bills would delete the DOL advice
and consent authority, and both bills
would hold TPA-certified optometrists to
the same standard of care as physicians.
However, Preprint SB 9 would state that
TPA-certified optometrists may use only
topical (no oral) TPAs for treating eyes
and the appendages and adnexa for any
anterior segment disease or pathological
condition. Under SB 510, TPA-certified
optometrists must agree to accept Medi-

Cal patients and would not be able to
administer drugs by injection or intravenously.
At its December meeting, the Board
voted to take an oppose position on Preprint SB 9, and unanimously agreed to
seek an author to carry its own TPA legislation.

U

LITIGATION
In United States v. Vision Service Plan,
No. 94CV02693, filed by the U.S. Department of Justice (DOJ) in U.S. District
Court for the District of Columbia in December 1994, the federal government alleged that California-based Vision Service
Plan (VSP), the country's largest vision
care insurance plan, violated section t of
the Sherman Act by illegally requiring
so-called "most favored nation" (MFN)
clauses in its contracts with optometrists.
According to DOJ, the MFN clause prohibits each VSP optometrist from charging VSP patients higher fees than those
charged non-VSP patients; requires VSP
optometrists to notify VSP if a published
VSP fee schedule exceeds their usual and
customary fee, and requires them to accept
the lower fee; and requires participating
optometrists to accept reduced fees if VSP
determines the optometrist has charged it
higher fees than those charged non-VSP
patients. According to Anne Bingaman,
assistant attorney general in charge of DOJ's
Antitrust Division, the MFN clause discourages optometrists from offering discounts to non-VSP patients from competing plans, and vision care insurance plans
that had previously contracted with optometrists at discounts between 20-40%
were no longer able to obtain those discounts.
On the same day it filed the lawsuit,
however, DOJ also filed a proposed consent decree which-if approved by the
court-would settle the matter. Under the
proposed consent decree, VSP will discontinue its practice of using the challenged MFN clause and will adopt a new
fee system based on a range of fees accepted by optometrists. Also pursuant to
the proposed consent decree, VSP would
be prohibited from maintaining, adopting,
or enforcing any policy or practice of linking payments made by VSP to any VSP
panel optometrist to fees charged by the
optometrist to any non-VSP patient or any
non-VSP plan; differentiating its payments to, or other treatment of, any VSP
panel optometrist because the optometrist
charges any fee lower than that charged by
the optometrist to the VSP, to any nonVSP patient, or to any non-VSP plan; taking any action to discourage any VSP panel
optometrist from participating in any non-
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VSP plan or from offering or charging any
fee lower than that paid to the optometrist
by VSP to any non-VSP patient or to any
non-VSP plan; monitoring or auditing the
fees that any VSP panel optometrist charges
any non-VSP patient or non-VSP plan;
and communicating in any fashion with
any VSP panel optometrist regarding the
his/her participation in any non-VSP plan
or regarding the his/her fees charged to
any non-VSP patient or to any non-VSP
plan. [15:2&3 CRLR 87; 15:1 CRLR 83841
On November 13, DOJ agreed to revise its final judgment and competitive
impact statement in response to VSP's
request to change the settlement because
it found it difficult to comply with operating agreements with states for which it
acts as agent for Medicaid or Medicare
programs under the agreement, and because it encountered difficulties in trying
to calculate fees for panel optometrists
under the terms of the original proposal.
Among other things, the revised agreement:
-permits VSP to implement the reimbursement methodologies of any Medicare program or any state Medicaid program it may administer, including collecting fee information, while precluding VSP
from using that fee information in setting
the fees that VSP pays its panel optometrists for providing services to VSP patients not covered by Medicare or Medicaid;
-eliminates VSP's ability to collect information and calculate payments to panel
optometrists based on modal or median
fees; and
-allows VSP to retain the option of
calculating the fees that it pays panels
optometrists based on their usual and customary fees, and permits VSP to ask each
panel optometrist to report annually only
the optometrist's usual and customary fees
before any discounts are applied and to
verify, if warranted, only the fee information.
At this writing, the court has not yet
approved the proposed consent decree.
In State of Florida v. Johnson &
Johnson, et al., No. 94-619-CIV-J-20, the
Florida Attorney General filed a nationwide class action in U.S. District Court for
the Middle District of Florida against
Bausch & Lomb Inc., Johnson & Johnson
Vision Products Inc., the American Optometric Association, the Contact Lens and
Anterior Segment Society, and nine optometrists; the Attorney General contends
that the defendants engaged in a conspiracy to restrict the sale of soft contact
lenses. According to the action, the defendants made soft contact lenses available
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only to optometrists, ophthalmologists,
and opticians-who often mark up the
lens prices significantly-and not to alternative channels of distribution such as
pharmacies, mail-order firms, and similar
entities which may offer discounted prices
on the lenses. The action further claims
that the named optometrists and the Society tried to persuade lens manufacturers
not to distribute soft lenses to alternative
chains of distribution, and that the Society
threatened not to prescribe the lenses of
any manufacturer which sold its product
to pharmacies or mail-order channels of
distribution. At this writing, the matter is
not expected to be heard until at least late
1996 or early 1997.

* RECENT MEETINGS
At its December 1-2 meeting, in response to questions regarding the amount
of time necessary to complete the rulemaking process, the Board reviewed the procedural requirements which must be met
in order to adopt, amend, or repeal a regulation; staff will also prepare and distribute a flowchart explaining the rulemaking
process as set forth in the Administrative
Procedure Act.
Also at its December meeting, the Board
reelected John Anthony, OD, to serve as
President; Robert Dager, OD, to serve as
Vice-President; and Mona Tawatao to serve
as Secretary.
* FUTURE MEETINGS
March 15-16 in Anaheim.
May 13-14 in San Jose.
August 22-23 in Sacramento.
November 18-19 in San Diego.

BOARD OF PHARMACY
Executive Officer: Patricia Harris
(916) 445-5014

p

ursuant to Business and Professions
Code section 4000 et seq., the Board
of Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manufacturers, wholesalers, medical device retailers, and sellers of hypodermic needles.
It regulates all sales of dangerous drugs,
controlled substances, and poisons. The
Board is authorized to adopt regulations,
which are codified in Division 17, Title
16 of the California Code of Regulations
(CCR). To enforce its regulations, the Board
employs full-time inspectors who investigate complaints received by the Board.
Investigations may be conducted openly
or covertly as the situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
114

law to suspend or revoke licenses or permits for a variety of reasons, including
professional misconduct and any acts substantially related to the practice of pharmacy.
The Board consists of ten members,
three of whom are nonlicensees. The remaining members are pharmacists, five of
whom must be active practitioners. All are
appointed for four-year terms.
In May 1995, Board member Kent
Wilcox resigned, but will continue to
serve until Governor Wilson appoints his
replacement.

U

MAJOR PROJECTS

Distribution of Drug Samples. On
May 24, the Board held an informational
hearing on the distribution of drug samples in California. Under the current system of distribution, sales representatives
of drug manufacturers supply physicians
with drug samples to be dispensed directly
to patients. The Board held the hearing to
receive comments on whether this system
provides the best approach to a patient's
drug therapy, and to explore alternative
approaches to the current system of drug
sample distribution.
An issue paper which accompanied the
Board's hearing notice identified the positive outcomes of drug sample therapy;
specifically, the Board stated that drug
sample distribution allows patients to begin
drug therapy immediately, reduces patient
costs, and allows physicians to readily test
a patient's reaction to the drug. However,
the Board expressed concerns that drug
samples are not monitored and accounted for
during their handling, transportation, and
distribution to physicians. Other unresolved
issues arising out of the distribution and
dispensing of drug samples include the fact
that no record of use or monitoring of the
drug therapy can be maintained by a pharmacist; without record of use, the pharmacist
is unable to evaluate a drug's interaction
with the patient's entire medication regimen
to prevent adverse reactions; the patient will
not receive counseling on the use of the drug
from a pharmacist; the potential for diversion of drug samples for unintended use by
patients; the unauthorized sale of samples by
pharmacies; the fact that unlicensed sales
representatives of drug manufacturers have
access to drugs with no state oversight of
storage conditions or means of accounting
for quantities dispensed; and the lack of a
means to track a drug sample if it is recalled.
The Board is considering an alternative to the current system of sample distribution through the use of a voucher/coupon method of distribution. Under this
proposal, a physician could issue a voucher
or coupon to a patient, allowing the patient

to receive a free sample quantity of a drug
from a pharmacy; the free amount that is
dispensed would then be billed to the manufacturer.
During the informational hearing, the
Board considered comments from manufacturers, practitioners, and representatives of professional associations in support of and in opposition to modifying the
existing system of drug sample distribution. In support of the status quo, Dr. Ben
Shwachman of the California Medical Association (CMA) stated that the Board has
not identified and proven that a problem
exists under the current system. Furthermore, CMA contends that current law adequately regulates manufacturers and physicians in the distribution and dispensing
of drug samples. Others in favor of the
current system noted that the alternative
voucher system would only add more
recordkeeping requirements and increase
costs; issues of distribution accountability
and control should not impair the availability of samples to the medically indigent; pharmacists' inability to update patient drug records is not a realistic justification to discredit the dispensing of drug
samples by physicians in light of the numerous prescriptions filled by out-of-state
pharmacies; physicians maintain documentation of sample drugs dispensed in
the patient's records along with results of
the medical examination for which the
drug therapy was recommended; and diversion is not a serious health concern
since samples do not include Schedule II
drugs.
In opposition to the current method of
dispensing drug samples, Robert Marshall
of the California Pharmacists Association
(CPhA) expressed support for the alternative voucher method of dispensing samples through a pharmacy. CPhA contends
that the proposed method would allow
entry of relevant data in the patient profile,
eliminate the waste of different packaging
used on sample sizes, afford patients adequate labeling not found on samples, and
provide the opportunity for oral consultation with a pharmacist. Those also opposed to the existing system of drug sample distribution emphasized that patients
to whom samples are dispensed are not
receiving drugs judged on their pharmacological merits but as a result of marketing
strategies. Other advocates of the proposed voucher system contend that the
alternative method of sample distribution
would better protect the public through the
services offered by a pharmacist and the
safeguards of drug accountability.
Following public comments, the Board
clarified that physicians are held to the
same standards required of pharmacists
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